JP2002503223A - 複数の活性分子を供与する分子 - Google Patents

複数の活性分子を供与する分子

Info

Publication number
JP2002503223A
JP2002503223A JP54407498A JP54407498A JP2002503223A JP 2002503223 A JP2002503223 A JP 2002503223A JP 54407498 A JP54407498 A JP 54407498A JP 54407498 A JP54407498 A JP 54407498A JP 2002503223 A JP2002503223 A JP 2002503223A
Authority
JP
Japan
Prior art keywords
group
multivalent
donor
poly
framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54407498A
Other languages
English (en)
Japanese (ja)
Inventor
ホワイトサイズ，ジョージ
タナンボーム，ジェイムズ・ビー
グリフィン，ジョン
マメン，マタイ
Original Assignee
アドバンスト・メディシン・インコーポレイテッド
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスト・メディシン・インコーポレイテッド, プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ filed Critical アドバンスト・メディシン・インコーポレイテッド
Publication of JP2002503223A publication Critical patent/JP2002503223A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/00756—Compositions, e.g. coatings, crystals, formulations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP54407498A 1997-04-11 1998-04-09 複数の活性分子を供与する分子 Pending JP2002503223A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4378197P 1997-04-11 1997-04-11
US4382697P 1997-04-14 1997-04-14
US60/043,781 1997-04-14
US60/043,826 1997-04-14
PCT/US1998/007171 WO1998046270A2 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs

Publications (1)

Publication Number Publication Date
JP2002503223A true JP2002503223A (ja) 2002-01-29

Family

ID=26720814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54407498A Pending JP2002503223A (ja) 1997-04-11 1998-04-09 複数の活性分子を供与する分子

Country Status (8)

Country Link
EP (1) EP0973551A2 (fr)
JP (1) JP2002503223A (fr)
KR (1) KR20010006280A (fr)
CN (1) CN1269013A (fr)
AU (1) AU743028B2 (fr)
BR (1) BR9808521A (fr)
CA (1) CA2286692A1 (fr)
WO (1) WO1998046270A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1079859B1 (fr) 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
JP3468149B2 (ja) * 1999-02-19 2003-11-17 松下電器産業株式会社 微細物体の操作装置および操作方法
EP1177029B1 (fr) * 1999-05-10 2004-03-17 Glaxo Group Limited Station de travail haute capacite de criblage de formes cristallines et son utilisation
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100543171B1 (ko) * 2002-05-31 2006-01-20 한국과학기술원 분자수준에서 배향성을 조절하면서 항체 단분자막을 제조하는 방법
EP1802349A1 (fr) * 2004-10-13 2007-07-04 Ilypsa, Inc. Preparations pharmaceutiques comprenant un oligosaccharide complexant les toxines et une particule polymere
EP1951279B1 (fr) 2005-10-08 2017-04-12 Apellis Pharmaceuticals, Inc. Compstatine et analogues de celle-ci pour des troubles de la vue
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
EP2139524A1 (fr) * 2007-03-23 2010-01-06 The Governors of the University of Alberta Polymères hétérobifonctionnels multivalents et leurs procédés d'utilisation
WO2009032605A2 (fr) * 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Inhibiteurs du virus de la grippe couplés à un polymère bifonctionnel
JP6522337B2 (ja) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP6618682B2 (ja) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
US20160010077A1 (en) * 2013-02-28 2016-01-14 The University Of Southern Mississippi Covalent Attachment of Bacteriophages (Phages) to Polymeric Surfaces
CA3001128A1 (fr) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Utilisation d'un analogue de compstatin a action prolongee pour le traitement d'un trouble oculaire medie par un complement
US11564995B2 (en) 2018-10-29 2023-01-31 Wisconsin Alumni Research Foundation Peptide-nanoparticle conjugates
KR20210084552A (ko) 2018-10-29 2021-07-07 위스콘신 얼럼나이 리서어치 화운데이션 향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머
WO2021087021A1 (fr) 2019-10-29 2021-05-06 Wisconsin Alumni Research Foundation Conjugués peptide-nanoparticule

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463314B (sv) * 1989-03-01 1990-11-05 Biocarb Ab Sampolymerer av en n-acylerad glykosylamin och en amid, n-akryloyl-eller metakryloylglykosylaminer samt foerfarande foer framstaellning av dessa
DE19640791A1 (de) * 1996-10-02 1998-04-16 Syntesome Ges Fuer Medizinisch Glycokonjugate als Inhibitoren der viralen Zelladhäsion

Also Published As

Publication number Publication date
KR20010006280A (ko) 2001-01-26
EP0973551A2 (fr) 2000-01-26
CN1269013A (zh) 2000-10-04
CA2286692A1 (fr) 1998-10-22
AU7106998A (en) 1998-11-11
WO1998046270A2 (fr) 1998-10-22
WO1998046270A3 (fr) 1999-01-07
AU743028B2 (en) 2002-01-17
BR9808521A (pt) 2000-05-23

Similar Documents

Publication Publication Date Title
JP2002503223A (ja) 複数の活性分子を供与する分子
Su et al. Carbohydrate-based macromolecular biomaterials
Wu et al. “Sweet” architecture-dependent uptake of glycocalyx-mimicking nanoparticles based on biodegradable aliphatic polyesters by macrophages
Hosta-Rigau et al. Cholesterol–a biological compound as a building block in bionanotechnology
ES2346319T5 (es) Nanopartículas
Yu et al. Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry
Arosio et al. Effective targeting of DC-sign by α-fucosylamide functionalized gold nanoparticles
Bartneck et al. Immunomodulatory therapy of inflammatory liver disease using selectin-binding glycopolymers
JP2010502713A (ja) 粘液を通る輸送を増強するための組成物および方法
Bian et al. One-pot synthesis of redox-labile polymer capsules via emulsion droplet-mediated precipitation polymerization
KR100354944B1 (ko) 제약조성물
WO2017002979A1 (fr) Vecteur d'administration de médicament, et composition le contenant
Van Driessche et al. pH-sensitive hydrazone-linked doxorubicin nanogels via polymeric-activated Ester scaffolds: Synthesis, assembly, and in vitro and in vivo evaluation in tumor-bearing zebrafish
Bartheldyová et al. N-Oxy lipid-based click chemistry for orthogonal coupling of mannan onto nanoliposomes prepared by microfluidic mixing: Synthesis of lipids, characterisation of mannan-coated nanoliposomes and in vitro stimulation of dendritic cells
JP2005535604A (ja) 治療剤を含むポリマーナノ物品
WO1998047002A2 (fr) Bibliotheques combinatoires de presentation polyvalente et leurs utilisations
Clauss et al. Design, synthesis and biological applications of glycopolypeptides
Kong et al. Benzylguanidine and galactose double-conjugated chitosan nanoparticles with reduction responsiveness for targeted delivery of doxorubicin to CXCR 4 positive tumors
US20040248801A1 (en) Methods and reagents for regulation of cellular responses in biological systems
Takano et al. Molecular bottlebrushes for immunostimulatory CpG ODN delivery: Relationship among cation density, complex formation ability, and cytotoxicity
Tollemeto et al. Mucoadhesive Dendrons Conjugated to Mesoporous Silica Nanoparticles as a Drug Delivery Approach for Orally Administered Biopharmaceuticals
JP2023543527A (ja) シアル酸リガンド修飾治療薬
WO2012167882A1 (fr) Composition pour l'administration par voie orale de substances biologiquement actives
Detwiler et al. Preparation and applications of artificial mucins in biomedicine
CN103154012B (zh) 聚丙基醚亚胺的糖树状聚体